Aclaris therapeutics reports first quarter 2025 financial results and provides corporate update

- multiple catalysts in immuno-inflammatory indications anticipated in 2025 and 2026 - - expected cash runway extended through the first half of 2028 - - phase 2 results received to date from chinese partner cttq provide clinical evidence of enhanced potency of bosakitug (ati-045) and opportunity for development partnerships - - investigational new drug (ind) application for bispecific antibody ati-052 cleared by u.s. food and drug administration - wayne, pa., may 08, 2025 (globe newswire) -- aclaris therapeutics, inc. (nasdaq: acrs), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2025 and provided a corporate update.
ACRS Ratings Summary
ACRS Quant Ranking